BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
08/10/26	€0.002000	0.00%
07/10/26	€0.002000	0.00%
06/10/26	€0.002000	0.00%
05/10/26	€0.002000	0.00%
02/10/26	€0.002000	0.00%

Real-time Euronext Bruxelles

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - BioSenic SA

Company calendar

Real-time Euronext Bruxelles 19:55:00 08/10/2026 +04			5-day change	1st Jan Change
0.002000 ^EUR	0.00%		0.00%	-13.04%

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	1.5M 1.68M 1.4M 1.27M 2.39M 163M 2.42M 16.82M 6.58M 82.75M 6.31M 6.18M 266M	P/E 2023	-0.29x	P/E 2024	-0.28x
Enterprise Value	28.84M 32.29M 26.9M 24.44M 45.99M 3.13B 46.43M 323M 126M 1.59B 121M 119M 5.11B	EV / Sales 2023	113x	EV / Sales 2024	286x
Free-Float	92.39%	Yield 2023 *	-	Yield 2024	-

Markets		Quality
Euronext Bruxelles	BIOS	Real-time
CBOE	0R55	Real-time
CBOE	BOTHEb	Real-time

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/09/25	Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/10/24	BioSenic S.A. Announces Executive Changes	CI
30/09/24	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/09/24	Bone Therapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
17/09/24	BioSenic Deputy CEO Steps Down	MT
17/09/24	Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO	CI
14/08/24	BioSenic Unit Secures European Patent for Multiple Sclerosis Treatment	MT
14/08/24	Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office	CI
13/08/24	BioSenic Grants of A Key Patent by the Japan Patent Office to Expand Protection of the Arsenic Trioxide Platform	CI
18/07/24	Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide Targeting Cgvhd	CI
05/07/24	BioSenic Seeks US Patent Extension for Sepsis Drug	MT

BioSenic SA Stock

Stocks

BIOS

BE0974280126

Pharmaceuticals

Valuation: BioSenic SA

Chart: BioSenic SA

Latest news: BioSenic SA

Analysts' recommendations: BioSenic SA

Press Releases: BioSenic SA

News in other languages: BioSenic SA

Quotes and Performance

Price Extremes

Managers and Directors: BioSenic SA

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

12-14	BioSenic : Report from Auditor on ESEF format 2024 Annual Report	PU
25/09/25	BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors	PU
29/08/25	BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024	PU
05/08/25	BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors	PU
01/07/25	BioSenic : announces partnership with 4Moving Biotech and secures its financing.	PU

05-07	BioSenic : Procuration pour l'actionnaire
05-07	BioSenic : Rapport annuel 2025
05-07	BioSenic : Communiqué de Presse - Convocation à l'Assemblée Générale Ordinaire
04-28	BioSenic : BIOS PR 2026 avril Denominator FR20260428
04-12	BioSenic : annonce l'émission de droits de souscription au bénéfice de membres du conseil d'administration

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.1
5 years	0		0.35
10 years	0		0.35

Director	Title	Age	Since
Jean-Luc Vandebroek BRD	Director/Board Member	55	01/01/2022
Eric Halioua CHM	Chairman	-	01/09/2025
Virginie Miath BRD	Director/Board Member	-	29/01/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSENIC SA	0.00%	0.00%	-16.67%	-97.87%	1.46M
ELI LILLY AND COMPANY	-1.61%	+1.72%	+38.30%	+106.93%	1,043B
JOHNSON & JOHNSON	-0.76%	-0.84%	+35.21%	+62.70%	618B
ABBVIE INC.	+0.39%	+4.81%	+17.81%	+83.77%	481B
MERCK & CO., INC.	-0.29%	-0.99%	+64.79%	+37.06%	351B
ROCHE HOLDING AG	+1.69%	+3.47%	+21.83%	+42.60%	338B
NOVARTIS AG	+1.10%	+2.11%	+11.42%	+34.80%	269B
ASTRAZENECA PLC	+1.45%	+1.55%	-6.85%	+11.04%	244B
AMGEN INC.	-1.37%	+0.04%	+38.29%	+52.33%	220B
GILEAD SCIENCES, INC.	+0.17%	-0.27%	+24.40%	+96.82%	182B
Average	+0.28%	+0.25%	+22.85%	+43.02%	374.67B
Weighted average by Cap.	+0.11%	+0.60%	+30.61%	+69.18%

	2023	2024
Net sales	336K 376K 313K 285K 536K 36.44M 541K 3.76M 1.47M 18.52M 1.41M 1.38M 59.55M	102K 114K 95.15K 86.44K 163K 11.06M 164K 1.14M 447K 5.62M 429K 420K 18.08M
Net income	-28.78M -32.23M -26.85M -24.39M -45.89M -3.12B -46.34M -322M -126M -1.59B -121M -118M -5.1B	-4.77M -5.34M -4.45M -4.04M -7.6M -517M -7.68M -53.4M -20.89M -263M -20.05M -19.61M -845M
Net Debt	28.04M 31.4M 26.16M 23.76M 44.72M 3.04B 45.15M 314M 123M 1.55B 118M 115M 4.97B	27.34M 30.61M 25.5M 23.17M 43.59M 2.96B 44.02M 306M 120M 1.51B 115M 112M 4.85B